Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy

Background: Burosumab, a recombinant anti-FGF23 monoclonal antibody, was recently introduced as a treatment for X-linked hypophosphatemia (XLH). Burosumab normalizes blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing pain. We aimed to explore the body composition an...

Full description

Bibliographic Details
Main Authors:	Avivit Brener, Yael Lebenthal, Roxana Cleper, Livia Kapusta, Leonid Zeitlin
Format:	Article
Language:	English
Published:	SAGE Publishing 2021-03-01
Series:	Therapeutic Advances in Endocrinology and Metabolism
Online Access:	https://doi.org/10.1177/20420188211001150

Similar Items

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
by: Rafi Brener, et al.
Published: (2022-08-01)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
by: Aaron Schindeler, et al.
Published: (2020-05-01)

Real‐world data of Brazilian adults with X‐linked hypophosphatemia (XLH) treated with burosumab and comparison with other worldwide cohorts
by: Maria Helena Vaisbich, et al.
Published: (2024-02-01)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
by: Margaux Gadion, et al.
Published: (2022-11-01)

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
by: Karine Briot, et al.
Published: (2023-02-01)

Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
by: Silvia Martín Ramos, et al.
Published: (2020-02-01)

The recommended starting dose of 0.4mg/kg burosumab is insufficient for most children with X-linked hypophosphatemia (XLH) - Results from the first treated patients in Sweden
by: Sigrun Hallgrimsdottir, et al.
Published: (2020-10-01)

Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia
by: Magda Wojtuś, et al.
Published: (2023-07-01)

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone
by: Diana-Alexandra Ertl, et al.
Published: (2022-11-01)

Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome
by: Lillian Abebe, et al.
Published: (2024-03-01)

Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial
by: Peter Kamenický, et al.
Published: (2020-10-01)

X-linked hypophosphatemia (XLH): Mutations compromising PHEX structure reflect a severe phenotype
by: Whyte, M, et al.
Published: (1999)

Effects of Burosumab Treatment on Two Siblings with X-Linked Hypophosphatemia. Case Report and Literature Review
by: Claudia Maria Jurca, et al.
Published: (2022-08-01)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
by: Yuichi Takashi, et al.
Published: (2022-12-01)

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives
by: Lothar Seefried, et al.
Published: (2023-07-01)

Sclerostin antibody improves alveolar bone quality in the Hyp mouse model of X-linked hypophosphatemia (XLH)
by: Kelsey A. Carpenter, et al.
Published: (2023-10-01)

Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
by: M. Zulf Mughal, et al.
Published: (2023-01-01)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
by: Lothar Seefried, et al.
Published: (2023-10-01)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
by: Gema Ariceta, et al.
Published: (2023-09-01)

Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations
by: Raja Padidela, et al.
Published: (2020-10-01)

Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study
by: Gabriel T. Mindler, et al.
Published: (2022-03-01)

Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
by: Manal Khadora, et al.
Published: (2021-12-01)

Cardiometabolic outcomes in children and adolescents with West syndrome
by: Inbar Gilboa, et al.
Published: (2021-09-01)

Presentation and Diagnosis of Pediatric X-Linked Hypophosphatemia
by: Kento Ikegawa, et al.
Published: (2023-02-01)

A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome
by: Lea Maria Merz, et al.
Published: (2022-05-01)

Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
by: Enrique Rodríguez-Rubio, et al.
Published: (2021-02-01)

Correction to: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population
by: Enrique Rodríguez-Rubio, et al.
Published: (2021-04-01)

Curative Effect Observation of Burosumab for Children and Adults with X-Linked Hypophosphatemicrickets
by: LIU Qingyang, et al.
Published: (2024-01-01)

Special Issue: “X-Linked Hypophosphatemia”
by: Seiji Fukumoto, et al.
Published: (2023-11-01)

Treatment of X-Linked Hypophosphatemia in Children
by: Toshihiro Tajima, et al.
Published: (2022-08-01)

Adult Presentation of X-Linked Hypophosphatemia
by: Nobuaki Ito
Published: (2022-07-01)

Impaired 1,25 dihydroxyvitamin D3 action and hypophosphatemia underlie the altered lacuno-canalicular remodeling observed in the Hyp mouse model of XLH.
by: Ye Yuan, et al.
Published: (2021-01-01)

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
by: Portale, A, et al.
Published: (2019)

P251: XLH molecular diagnoses and the PHEX gene variant landscape: Sponsored hypophosphatemia gene panel testing findings from 2019 vs 2022
by: Nicole Miller, et al.
Published: (2023-01-01)

FURTHER LOCALIZATION OF THE GENE FOR X-LINKED HYPOPHOSPHATEMIA
by: Read, A, et al.
Published: (1987)

Impact of X-Linked Hypophosphatemia on Muscle Symptoms
by: Cecilia Romagnoli, et al.
Published: (2022-12-01)

Complications and Treatments in Adult X-Linked Hypophosphatemia
by: Yasuo Imanishi, et al.
Published: (2022-09-01)

X-Linked Hypophosphatemia Transition and Team Management
by: Takuo Kubota
Published: (2022-07-01)

Dental management of patients with X-linked hypophosphatemia
by: Bin-Na Lee, et al.
Published: (2017-05-01)

Genotype and Phenotype Analysis in X-Linked Hypophosphatemia
by: Peong Gang Park, et al.
Published: (2021-08-01)